NCT02511340 - A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | Biotech Hunter

Enrollment

167

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG

Flumatinib mesylate tablet 600 mg qd

Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients

Trial Locations (1)

Union Hospital Tongji Medical College Huazhong University of Science and technology, Wuhan